In this initial episode, neurologist Mike Sharma, MD, explains the biological rationale for inhibiting factor XIa and how its unique mechanism may allow stroke prevention with minimal bleeding risk.
Targeting Factor XIa: Redefining Secondary Stroke Prevention
This segment outlines the objectives, patient population, and conduct of the phase 3 OCEANIC-STROKE trial evaluating asundexian for secondary stroke prevention.
In episode 3, Mike Sharma, MD, reviews findings from the phase 2 PACIFIC-STROKE trial and explains how its results informed the design and dose selection for OCEANIC-STROKE.
In this final iteration, neurologist Mike Sharma, MD, reflects on how rapid diagnostics, comprehensive vascular management, and novel therapies are redefining the approach to secondary stroke prevention.
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
CTAD Presentation Lays Insights Into Disappointing Phase 3 EVOKE Trial of GLP-1 Semaglutide in Alzheimer Disease
2
Newly Launched Phase POLARIS-AD Trial Tests Oral Therapy AR1001 for Early Alzheimer Disease
3
Analyzing Subgroup Data From the TRAILBLAZER-ALZ 2 Study of Donanemab: Brandy Matthews, MD
4
Merck’s Novel Antibody MK-2214 Receives FDA Fast-Track Designation Following Phase 1 Results
5
